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Abstract Non-thyroidal illness is characterized by low tri-
iodothyronine (T3) serum level under acute-phase condi-
tions. We studied hepatic gene expression of the newly
identified thyroid hormone receptor (TR) cofactor DOR/
TP53INP2 together with TRs in a rat model of aseptic
abscesses induced by injecting intramuscular turpentine-oil
into each hindlimb. Afast (4-6h) decrease inthe serum level
of free thyroxine and free T3 was observed. By immunohis-
tology,abundantDORproteinexpressionwasdetectedinthe
nuclei of hepatocytes and ED-1
+ (mononuclear phagocytes),
CK-19
+ (biliary cells), and SMA
+ (mesenchymal cells of
the portal tract) cells. DOR signal was reduced with a
minimum at 6-12 h after the acute-phase reaction (APR).
Immunohistology also showed a similar pattern of protein
expression in TRα1 but without a significant change during
APR. Transcripts specific for DOR, nuclear receptor co-
repressor 1 (NCoR-1), and TRβ1 were down-regulated
with a minimum at 6-12 h, whereas expression for TRα1
and TRα2 was slightly and significantly up-regulated,
respectively, with a maximum at 24 h after APR was
initiated. In cultured hepatocytes, acute-phase cytokines
interleukin-1β (IL-1β) and IL-6 down-regulated DOR and
TRβ1 at the mRNA level. Moreover, gene expression of
DOR and TRs (TRα1, TRα2, and TRβ1) was up-regulated
in hepatocytes by adding T3 to the culture medium; this up-
regulation was almost completely blocked by treating the
cells with IL-6. Thus, TRβ1, NCoR-1, and the recently
identified DOR/TP53INP2 are abundantly expressed and
down-regulated in liver cells during APR. Their down-
regulation is attributable to the decreased serum level of
thyroid hormones and most probably also to the direct
action of the main acute-phase cytokines.
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Acute-phase reaction (APR) is the response of the body
to tissue injury. It is clinically characterized by fever,
weakness, adynamia, somnolence, and loss of appetite.
Leucocytosis, an increased erythrocyte sedimentation
rate, dramatic changes in serum levels of acute-phase
proteins, and a change in serum levels of several
hormones are observed in the blood. In addition to the
up-regulation of the serum level of corticosteroids, the
concentration of thyroid hormones (THs) decreases
(Bartalena et al. 1994). Metabolic changes during APR
are attributable to the effects of interleukin (IL)-1-like beta
(IL-1β), tumor necrosis factor-α, and IL-6-like cytokines
(IL-6, oncostatin M, and others), through the activation of
transcription factors, i.e., nuclear factor kappa B, activator
protein 1, signal transducer and activator of transcription
3/5, or CCAAT/enhancer-binding protein β.T h e s es i g n a l -
ing cascades result in increased plasma levels of a number
of positive acute-phase proteins (APPs), including clotting
proteins, transport proteins, antiproteases, and complement
factors, with a parallel decrease in negative APPs, such as
albumin or transferrin (Ramadori and Christ 1999).
Synthesis of the major APPs can be increased up to
1000-fold over normal levels under acute-phase condi-
tions. This group includes serum amyloid A and either C-
reactive protein in humans or its homolog in mice
(Ramadori et al. 1985a) and alpha-2 macroglobulin in rat
hepatocytes (Pierzchalski et al. 1992).
The state of altered TH metabolism observed under
acute-phase conditions is called non-thyroidal illness
(NTI), which is characterized by decreased serum TH
levels (De Groot 1999). Indeed, during the acute-phase
response induced by tissue injury, significant changes
take place in the regulation of TH serum levels and in
the molecules involved in signaling pathways. The
mechanisms inducing the changes at various levels of
synthesis and of THs (NTI) action during APR are still
poorly defined. Although the possibility of inducing
normal thyroxine (T4) and 3,3',5-triiodothyronine (T3)
plasma levels in intensive-care patients through hormonal
stimulation of the anterior pituitary gland has been shown
(Van den Berghe et al. 1999), the changes observed
during the acute phase might be part of the defense
strategy of the body. Indeed, therapeutic administration
of THs to intensive-care patients might improve meta-
bolic parameters (Van den Berghe et al. 1999, 2002)b u t
not the patient outcome (Becker et al. 1982;B r e n ta n d
Hershman 1986).
T3, the biologically active form of TH, plays a central
role in metabolic homeostasis, development, cell differ-
entiation, and growth under normal metabolic conditions
(Fowden 1995;Y e n2001). THs act at the cellular level
through diverse receptors. The gene expression of recep-
tors is known to be dependent on the hormone level. T3
regulates gene expression by interacting with isoforms of
the TH receptor (TR) derived from two different genes,
viz., TRα and TRβ (Brent et al. 1989a, 1989b). TRs are
differentially distributed in various tissues and during
developmental stages, indicating distinct and specific
functional roles. TRα is mainly present in the central
nervous system and muscle but is also found in the liver
(Amma et al. 2001;E r c a n - F a n ge ta l .1996). In liver, two
isoforms of TRα are present: the canonical TRα1a n dt h e
alternatively spliced TRα2, which lacks the T3-binding
domain and therefore acts as the dominant negative
inhibitor of TRα1a n dT R β1 at higher concentrations
( L a u d e te ta l .1991). The predominant active form of TR
in a murine liver cell line is TRβ1 (Ventura-Holman et al.
2007), but another report also underlines the important
role of TRα in the liver (Macchia et al. 2001). In addition,
TRα2h a sb e e ns h o w nt oh a v ea ni n h i b i t o r ye f f e c to nt h e
other TR isoforms (Koenig et al. 1989). Recent experi-
ments with knockout mice have demonstrated that absence
of both TRαso rT R α 2 alone results in a higher T3
sensitivity; this has been hypothesized to be attributable to
the inhibitory effect of TRα2, which is missing in these
knockout mice (Macchia et al. 2001). Another TH co-
repressor protein, called nuclear receptor co-repressor 1
(NCoR-1; Horlein et al. 1995), is known to promote
chromatin condensation and prevents access to the
transcription machinery in the gene transcription regulated
by the TR and retinoic X receptor (Grignani et al. 1998;
Horlein et al. 1995).
Recently, a novel component of TH action, DOR/
TP53INP2, has been identified, which is repressed in
diabetic rat muscle. DOR is localized within the nucleus
and has been shown to be crucial for the transcriptional
regulation of T3-controlled genes by direct interaction with
TRα1 (Baumgartner et al. 2007).
In the present study, we have demonstrated that the
TRs are down-regulated in the liver and liver cells in a
rat model of APR. This may be attributable not only to a
reduced TH serum level, but also to the direct effect of
acute-phase mediators on the regulation of the TR gene
expression in liver cells, possibly explaining the lack of
clinical effectiveness of T3 administration under acute-
phase conditions.
Materials and methods
Animals
Male Wistar rats of about 170-200 g body weight were
purchased from Harlan-Winkelmann (Brochen, Germany).
262 Cell Tissue Res (2010) 342:261–272The rats were kept under standard conditions with 12 h
light/dark cycles and ad libitum access to fresh water and
food pellets. All animals were cared for according to the
University’s guidelines, the German convention for the
protection of animals, and NIH guidelines.
Antibodies
A mouse monoclonal antibody directed against CK-19
(marker for biliary cells) was purchased from Novocastra
(Newcastle upon Tyne, UK), a mouse monoclonal antibody
directed against smooth muscle actin (SMA) from Sigma
(Munich, Germany), a rabbit polyclonal anti-TRα1 from
Abcam (Cambridge, UK), and a mouse anti-rat ED-1
(marker for mononuclear phagocytes) monoclonal antibody
from Serotec (Duesseldorf, Germany). A rabbit polyclonal
antibody directed against human DOR/TP53INP2 (a TR co-
factor) was a gift from Prof. Antonio Zorzano (University
of Barcelona, Spain). Detection by immunofluorescence
was carried out as described previously (Malik et al. 2010).
Induction of APR
APR was induced in ether-anesthetized rats by intramuscu-
lar injection of 5 mg/kg turpentine oil (TO) into both the
right and left hind limbs of the animals. Control animals
were treated in the same way for each time-point with
saline injection into both limbs. Animals were killed 0.5, 1,
2, 4, 6, 12, 24, 36, 48, 60, and 72 h after TO injection under
pentobarbital anesthesia. Livers were excised, rinsed with
physiological sodium saline, snap-frozen in liquid nitrogen,
and stored at -80°C until further use.
Measurement of free thyroxine and free tri-iodothyronine
levels
At time-points ranging from 1-24 h after TO injection,
blood samples from the inferior vena cava were collected
from controls and TO-injected rats and used for the
detection of free thyroxine (FT4) and free tri-
iodothyronine (FT3) levels in the serum of rats by using a
standard protocol (University Medical Center, Göttingen).
Immunofluorescent staining
Double-immunofluorescence was performed according to
a protocol described previously (Malik et al. 2010).
Briefly, cryostat sections (~5 μm thick) were fixed in
acetone for 10 min. Afterwards, the rabbit polyclonal
primary antibody against DOR and a mouse monoclonal
anti-CK-19, a rabbit monoclonal anti-α-SMA, and a
mouse monoclonal anti-ED-1 primary antibody (1:50)
were incubated with the sections overnight at 4°C.
Primer 5′——3′ Forward 5′——3′ Reverse
TRα1 TGCCCTTACTCACCCCTACA AAGCCAAGCCAAGCTGTCCT
TRα2 TGAGCAGCAGTTTGGTGAAG GAATGGAGAATTCCGCTTCG
TRβ1 AGCCAGCCACAGCACAGTGA CGCCAGAAGACTGAAGCTTGC
NCoR-1 AGTCGCTACAGCCCAGAGTC CTCCTCTCTGGGGATTTTCC
DOR AACCACAGCCTGCTTCTAATACCTT TCAGCCAGTCTCAACACAAAACAC
β-Actin ACCACCATGTACCCAGGCATT CCACACAGAGTACTTGCGCTCA
UBC CACCAAGAAGGTCAAACAGGAA AAGACACCTCCCCATCAAACC
Table 1 Rat primer sequences
used (TR thyroid hormone
receptor, NCoR nuclear receptor
co-repressor, DOR TR co-factor,
UBC ubiquitin C)
Fig. 1 Serum-free thyroxine (FT4; a) and free tri-iodothyronine (FT3;
b) levels in rats during acute-phase reaction (APR). Values on the y-
axis are serum concentration values of FT3 and FT4 measured
compared with saline-treated controls. Results represent means±SEM
of three animals; *P<0.05
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saline (PBS), incubation was carried out with Alexa-Fluor-
conjugated goat anti-rabbit and anti-mouse secondary
antibody (1:200; Molecular Probes, Germany) at room
temperature for 1 h. The sections were washed 3 times for
5 min in PBS. Finally, nuclei were stained with 4,6-
diamidino-2-phenylindole (DAPI), and sections were
washed and mounted.
Protein isolation and Western blot analysis
Proteins were isolated as described previously (Tron et al.
2005). Livers at various time-points after TO treatment
were lysed in hot Laemmli buffer (95°C) and processed
with sodium dodecyl sulphate polyacrylamide gel electro-
phoresis under reducing conditions according to (Laemmli
1970). The protein content of the cellular lysates was
calculated by the Coomassie Protein Assay (Pierce,
Germany) in which β-actin was used as the loading control.
Proteins were transferred onto Hybond–ECL nitrocellulose
hybridization transfer membranes according to Towbin et
al. (1979). We performed immunodetection studies accord-
ing to the ECL Western blotting protocol of GE Healthcare
(Germany). The primary antibody to DOR was used at a
1:100 dilution, whereas the anti-rabbit immunoglobulins
were each used at a 1:2000 dilution.
Isolation of hepatocytes and culture conditions
Hepatocytes were isolated from normal animals according
to Seglen (1972) with the modification as described in
Ramadori et al. (1990). The purity of the isolated cell
populations was determined by phase-contrast microscopy
and by immunocytochemistry with antibodies against
laminin or glial fibrillary acidic protein in order to identify
stellate cells (both by Sigma, Germany) or ED-1 and ED-2
Fig. 2 Double-staining of liver sections with polyclonal antibody
directed against DOR (red) and monoclonal antibody against human
CK-19 (green) followed by fluorescence immunodetection in sections
of rat liver during APR after TO treatment. a Control liver. Inset
Higher magnification of boxed area in a. b At 6 h after TO treatment.
c At 12 h after TO treatment. d At 24 hours after TO treatment.
Representive results from three animals and six slides per time-point.
Original magnification: ×200. Bars 100 μm
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phages. The cells were incubated at 37°C in a 95% air/5%
CO2 atmosphere. DMEM (Biochrom, Germany) was
supplemented with 10% fetal calf serum (PAA, Germany),
0.05% insulin (Roche, Germany), and 10
-7 dexamethasone
(Sigma, Germany). Hepatocytes were exposed to a single
treatment of 100 ng/ml recombinant IL-6 and IL-1β
(PeproTech, Germany) after a dose-dependent (10, 100,
and 1000 ng/ml) study at 6 and 12 h following stimulation,
for both cytokines in 3 ml cell-culture medium. Cells were
also stimulated with 100 nM T3 in 3 ml cell-culture
medium in the presence or absence of IL-6 as described
previously (Dace et al. 2000;S h e i k he ta l .2006).
Hepatocytes were harvested in all in vitro experiments at
1, 3, 6, 12, and 24 h after cytokine treatment. Non-treated
cells at all studied time-points served as controls in all
experiments.
RNA isolation and quantitative real-time polymerase chain
reaction
Total RNA was isolated from liver samples and
hepatocytes by means of guanidine isothiocyanate
extraction, caesium chloride density-gradient ultracentri-
fugation, and ethanol precipitation according to a
previously described method (Chirgwin et al. 1979), with
some modifications as described elsewhere (Ramadori et
al. 1985b). The RNA obtained was quantified by
measuring the absorbance at 260 nm. cDNAwas generated
by reverse transcription of 1 mg total RNA with 100 nM
dNTPs, 50 pM primer oligo(dT)15, 200 U Moloney murine
leukemia virus reverse transcriptase, 16 U protector RNase
inhibitor, 1× reverse transcription buffer, and 2.5 ml 0.1 M
dithiothreitole for 1 h at 40°C. Gene expression was
analyzed by using Platinum SybrGreen qPCR mix UDG
Fig. 3 Double-staining of liver sections with polyclonal antibody
directed against DOR (red) and monoclonal antibody against human
SMA (green) followed by fluorescent immunodetection in sections of
rat liver during APR after TO treatment. a Control liver. Inset Higher
magnification of boxed area in a. b At 6 h after TO treatment. c At
12 h after TO treatment. d At 24 hours after TO treatment. DOR-
positive cell numbers decreased in liver during APR. Representive
results from three animals and six slides per time-point. Original
magnification: ×200. Bars 100 μm
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tin C (UBC) and β-actin were used as normalizers. The
primer sequences used are shown in Table 1. Amplifi-
cation was performed at 95–6 0 ° Cf o r4 5c y c l e si na n
ABI prism 7000 sequence detection system. All samples
were assayed in duplicate. The results were normalized
to the housekeeping gene, and the fold-change in
expression was calculated by using threshold cycle
values.
Statistical analysis
The data were analyzed by using Prism Graph Pad 4
software (San Diego, USA). All experimental errors are
shown as SEM. Statistical significance was calculated by
Student’s -test, one-way analysis of variance, and
Dunnett’s post hoc tests. Significance was accepted at
P<0.05.
Results
Changes in FT4 and FT3 serum levels in rats during APR
The FT3 serum level was significantly decreased below
control values at 4 h after TO injection; this reduction lasted
up to 72 h with a minimum of 60 h. A similar pattern was
also observed for FT4 at the serum level (Fig. 1a, b).
Subcellular DOR and TRα1 localisation in liver sections
from untreated and APR animals
DOR protein was detected in the large nucleus of hepatocytes
and was organized in well-defined spots, similar to that in
HeLa cells (Baumgartner et al. 2007). The intensity of the
DOR dots decreased 6–12 h after APR was initiated and
began to increase thereafter (Fig. 2). Double-staining of
biliary cells (CK-19
+), mesenchymal cells (SMA
+), and
Fig. 4 Double-staining of liver sections with polyclonal antibody
directed against DOR (red) and monoclonal antibody against human
ED-1 (green) followed by fluorescent immunodetection in sections of
rat liver during acute-phase response after TO treatment. a Control
liver. Inset Higher magnification of boxed area in a. b At 6 h after TO
treatment. c At 12 h after TO treatment. d At 24 hours after TO
treatment. Representive results from three animals and six slides per
time-point. Original magnification: ×200. Bars 100 μm
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+) also revealed DOR-positive dots in
these cells. The intensity of dots decreased in CK-19
+ cells,
SMA
+, and in ED-1
+ cells during APR (Figs. 2, 3, 4).
Strong nuclear positivity for TRα1 was found in liver
sections from untreated animals and was evenly distributed
in periportal and pericentral areas. In addition, positive dots
were also noted around the cells of vessel walls of portal
and central areas. Immunohistology revealed no significant
change in the protein expression of TRα1 at any time-point
during APR (Fig. 5a–f).
DOR protein level in liver tissue during APR
In accordance with the immunohistological detection, DOR
protein levels decreased in nuclei during APR as detected by
Western blot analysis of nuclear extracts. At the same time, the
concentration of HO-1 protein, a positive control for APR,
peaked at 12 h during APR, as previously described, confirm-
ing successful APR induction (Tron et al. 2005;F i g .6a, b).
Fig. 5 Immunofluorescent
staining of liver sections with
polyclonal antibody directed
against TRα1( green) followed
by fluorescence immunodetec-
tion in sections of rat liver
during APR after TO treatment.
a, c, e Control liver. b, d, f At
6 h after TO treatment. a, b
Anti-TRα1 and 4,6-diamidino-
2-phenylindole (DAPI) staining
(blue). c, d Anti-TRα1 staining.
e, f DAPI staining. Insets Higher
magnification of respective
boxed areas. Inset in a Anti-
TRα1 and DAPI staining
(arrows cells of portal area are
also positive for TRα1). Inset in
c Anti-TRα1 staining alone.
Representive results from three
animals and six slides per time-
point (PV portal vein, CV central
vein). Original magnification:
×200. Bars 100 μm
Fig. 6 Western blot analysis of protein from rat liver under APR
conditions at various time-points with antibodies specific for (a) HO-1
and β-actin and for (b) DOR and β-actin using total protein and
nuclear extract, respectively
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tissue
A decrease of DOR gene expression from 30 min to 24 h,
reaching a minimum at 6 h, could be observed after the
onset of the acute phase. Accordingly, a significant down-
regulation of NCoR-1-specific mRNA was found with a
minimum at 6 h (Fig. 7a). TRβ1 was slightly up-regulated
in the early phase followed by a significant down-
regulation with a minimum at 12 h and normalization of
mRNA levels by 48 h. A down-regulation was also
observed in the later phase lasting up to the 72-h time-
point. TRα1 steady state mRNA levels did not change
during APR, whereas TRα2 showed significant up-
regulation, which peaked at 4 h after treatment followed
by down-regulation with minimum expression 60 h after
treatment (Fig. 7b).
Modulation of TR gene expression in cultured rat
hepatocytes
DOR mRNA level in hepatocytes significantly decreased
compared with untreated controls upon exposure to IL-6 or
IL-1β. The most pronounced decrease was observed at 6
Fig. 7 Quantitative reverse transcription with polymerase chain
reaction (qRT-PCR) analysis of total RNA from rat liver during
APR. Fold-change in mRNA expression of DOR, NCoR1, TRα1,
TRα2, and TRβ1 in the TO-treated liver at various time-points (1-
72 h) relative to saline-treated controls for each time-point. qRT-PCR
was normalized by using two housekeeping genes: β-actin and
ubiquitin C. Results represent means±SEM of three animals; *P<0.05
268 Cell Tissue Res (2010) 342:261–272and 12 h after the start of cytokine treatment. The effect of
IL-6 on reducing DOR expression was stronger than that
induced by IL-1β treatment. Similarly, an early (3-6 h)
down-regulation of TRβ1 was also observed after treatment
with IL-6 or IL-1β. The impact of IL-6 was also stronger
than IL-1β in cultured hepatocytes. No significant change
in the gene expression of NCoR-1 was observed after IL-6
exposure; however, a rapid significant reduction (1-6 h)
was detected after IL-1β treatment. In contrast, an early
(1 h) up-regulation of TRα1 and TRα2 was observed after
treatment with IL-6 followed by a slight down-regulation
thereafter. Surprisingly, a fast down-regulation (1 h) of both
genes was detected followed by up-regulation at 3-6 h in
hepatocytes when treated with IL-1β (Figs. 8, 9).
T3 treatment of hepatocytes significantly induced early
gene expression of DOR, NCoR-1, and TRα1 and this
steadily increased with a maximum at 24 h. An early
significant up-regulation at 1 h was also detected for the
gene expression of TRα2 and TRβ1 with a maximum of
induction at 12 h. The up-regulating effect was completely
cancelled by the addition of IL-6 to the culture medium
(Fig. 8).
Discussion
In the present study, we investigated the expression levels of
key receptors of the THs mainly responsible for hormone
Fig. 8 qRT-PCR analysis of total RNA from isolated rat hepatocytes
treated with IL-6, T3, or IL-6+T3. Data are shown as fold-changes in
mRNA expression of DOR, NCoR-1, TRα1, TRα2, and TRβ1a t
various time-points relative to untreated controls for each time-point.
qRT-PCR was normalized by using two housekeeping genes: β-actin
and ubiquitin C. Results represent means±SEM of three experiments;
*P<0.05
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newly identified TR cofactor DOR/TP53INP2, in the rat liver
during APR in parallel with the serum level of the THs. In
isolated hepatocytes treated with acute-phase mediators, with
or without TH, we also studied changes of TR gene
expression. The results of the current study demonstrate that
hepatocytes, macrophages, mesenchymal cells, and bile duct
cells express abundant amounts of nuclear DOR with a
decrease during the first 6-24 h of APR. In contrast, TRα1
immunoreactivity shows a uniform, equally distributed, and
constant nuclear positivity throughout the liver. In accordance
with the immunohistology and Western blot analysis, DOR
gene expression is also down-regulated at the mRNA level in
the liver. Commensurate with the down-regulation observed
for the DOR gene, similar patterns of expression have been
detected for TRβ1 and NCoR-1 at the mRNA level, whereas
TRα1 is only slightly up-regulated, and TRα2i ss i g n i f i c a n t l y
up-regulated during APR.
To address the question of whether the reduction in DOR
and TRβ1 gene expression during APR might have also been
attributable to the direct effect of acute-phase mediators (IL-6
and IL-1β) on the genes studied, a major population of the
liver cells (hepatocytes) was isolated and treated with two
“major” acute-phase cytokines (IL-6 and IL-1β). Similar to
the observations in the liver tissue during APR, a reduction in
gene expression of DOR and TRβ1 was found after treatment
with acute-phase cytokines (IL-6 and IL-1β). Likewise, an
up-regulationofTRα1 and the negative factor TRα2wasalso
observed. Whereas treatment of hepatocytes with T3 in-
creased the gene expression of DOR and of the other TRs,
such an increase was inhibited completely by the addition of
IL-6 to the culture medium.
THs are known to regulate gene expression through
receptors (TRs: TRα and TRβ), and changes in their gene
expression are accompanied by progressive changes in TH
level (Brent et al. 1989b).
Our current study has shown that transcription of T3-
controlled TR genes is severely affected during APR; this
might be more dependent on cytokines and the TH level
than on the TH level alone. The association between acute-
phase cytokines and TH might entail a causal link, as we
have found that the T3 signaling molecules TRβ1, DOR,
and NCoR1 are down-regulated in the liver during APR,
whereas the negative signaling factor TRα2 is up-regulated.
Tissue injury induces an acute-phase response, which is a
major mechanism of the body to restore homeostasis; APR
is heavily regulated by inflammatory cytokines such as IL-6
(Ramadori and Christ 1999; Sheikh et al. 2006) and is
negatively related to serum T3 levels (Bartalena et al.
1994). Thus, the involvement of acute-phase cytokines in
the pathogenesis of APR classifies NTI as part of the acute-
phase response.
Fig. 9 qRT-PCR analysis of
total RNA from isolated rat
hepatocytes treated with IL-1β.
Data are shown as fold-changes
in mRNA expression of DOR,
NCoR-1, TRα1, TRα2, and
TRβ1 at various time-points
relative to untreated controls for
each time-point. qRT-PCR was
normalized by using two house-
keeping genes: β-actin and
ubiquitin C. Results represent
means±SEM of three experi-
ments; *P<0.05
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expression of the newly identified gene DOR is attributable
not only to the decrease in TH serum concentration, but
possibly also to the direct effect of acute-phase cytokines
produced during APR on hepatocytes. Our study is
moreover the first to show that the expression of the newly
identified gene DOR is similar to that of the major TR, viz.,
TRβ1, in rat liver under APR.
The gene expression of TRs in NTI has been partially
described in previous studies. However, the clinical
impact, with a comprehensive study of major TRs,
including the newly identified gene DOR, under acute-
phase conditions has not been previously established.
Furthermore, previous reports examining the changes in
expression of TRs in models of NTI also show somewhat
conflicting findings.
Boelen et al. (2006) have reported a rapid decrease in
liver TRβ1 mRNA after lipopolysaccharide (LPS) admin-
istration in an animal model of APR. A lowering of TRβ1
mRNA in response to IL-1β also occurs in vitro in a
hepatoma cell line (Kwakkel et al. 2006). In the rabbit
model of prolonged (7 days) burn injury, TRs are
unchanged in the hypothalamus-pituitary-thyroid axis
(Mebis et al. 2009).
In contrast to treatments inducing an acute systemic
response and also liver damage, such as the administra-
tion of the bacterial endotoxin LPS (Boelen et al. 2006),
TO is known to induce aseptic local abscesses without
detectable injury to other tissues (Ramadori and Meyer
Zum Buschenfelde 1990;T r o ne ta l .2005;W u s t e m a ne t
al. 1990). Therefore, the TO-induced APR model allows
us to study the effect of cytokines produced at distant sites
to the liver. It reproduces the changes observed in human
disease states caused by localized tissue injury (Gabay
and Kushner 1999; Halter et al. 2005; Kim et al. 2002;
Stoeck et al. 2006) making it an ideal model for studying
human APR. Use of this model in the current study is also
of special interest as the down-regulation of TRβ1a n d
up-regulation of TRα2 have been observed, which might
be attributable to the inhibitory effect of TRα2o nT R β1,
as previously reported (Koenig et al. 1989). This fact has
not been reported in any other acute-phase animal model
so far.
In conclusion, our data suggest that therapeutic replace-
ment under acute-phase conditions might not be effective,
as activating TRs are not available, and their inhibitor
(TRα2) is up-regulated at the same time.
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